• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2017 National Institute for Health and Care Excellence (NICE) Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. NICE technology appraisal guidance 429
2017 National Institute for Health and Care Excellence (NICE) Sofosbuvir-velpatasvir for treating chronic hepatitis C. NICE technology appraisal guidance 430
2017 National Institute for Health and Care Excellence (NICE) Everolimus for advanced renal cell carcinoma after previous treatment. NICE technology appraisal guidance 432
2017 National Institute for Health and Care Excellence (NICE) Apremilast for treating active psoriatic arthritis. NICE technology appraisal guidance 433
2017 National Institute for Health and Care Excellence (NICE) Elotuzumab for previously treated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 434
2017 National Institute for Health and Care Excellence (NICE) Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal). NICE technology appraisal guidance 435
2017 National Institute for Health and Care Excellence (NICE) Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 436
2017 National Institute for Health and Care Excellence (NICE) Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal). NICE technology appraisal guidance 437
2017 National Institute for Health and Care Excellence (NICE) Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 438
2017 National Institute for Health and Care Excellence (NICE) Cetuximab and panitumumab for previously untreated metastatic colorectal cancer. NICE technology appraisal guidance 439
2017 National Institute for Health and Care Excellence (NICE) Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine. NICE technology appraisal guidance 440
2017 National Institute for Health and Care Excellence (NICE) Ixekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 442
2017 National Institute for Health and Care Excellence (NICE) Obeticholic acid for treating primary biliary cholangitis. NICE technology appraisal guidance 443
2017 National Institute for Health and Care Excellence (NICE) Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 444
2017 National Institute for Health and Care Excellence (NICE) Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 445
2017 National Institute for Health and Care Excellence (NICE) Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia. NICE technology appraisal guidance 450
2017 National Institute for Health and Care Excellence (NICE) Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. NICE technology appraisal guidance 451
2017 National Institute for Health and Care Excellence (NICE) Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal). NICE technology appraisal guidance 452
2017 National Institute for Health and Care Excellence (NICE) Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal). NICE technology appraisal guidance 453
2017 National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 454
2017 National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. NICE technology appraisal guidance 455
2017 National Institute for Health and Care Excellence (NICE) Ustekinumab for moderately to severely active Crohn's disease after previous treatment. NICE technology appraisal guidance 456
2017 National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2017 National Institute for Health and Care Excellence (NICE) Adalimumab and dexamethasone for treating non-infectious uveitis. NICE technology appraisal guidance 460
2017 National Institute for Health and Care Excellence (NICE) Roflumilast for treating chronic obstructive pulmonary disease. NICE technology appraisal guidance 461
2017 National Institute for Health and Care Excellence (NICE) Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 462
2017 National Institute for Health and Care Excellence (NICE) Bisphosphonates for treating osteoporosis. NICE technology appraisal guidance 464
2017 National Institute for Health and Care Excellence (NICE) Baricitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 466
2017 National Institute for Health and Care Excellence (NICE) Holoclar for treating limbal stem cell deficiency after eye burns. NICE technology appraisal guidance 467
2017 National Institute for Health and Care Excellence (NICE) Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal). NICE technology appraisal guidance 468
2017 National Institute for Health and Care Excellence (NICE) Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal). NICE technology appraisal guidance 469
2017 National Institute for Health and Care Excellence (NICE) Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. NICE technology appraisal guidance 473
2017 National Institute for Health and Care Excellence (NICE) Sorafenib for treating advanced hepatocellular carcinoma. NICE technology appraisal guidance 474
2017 National Institute for Health and Care Excellence (NICE) Dimethyl fumarate for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 475
2017 National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer. NICE technology appraisal guidance 476
2017 National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma. NICE technology appraisal guidance 478
2017 National Institute for Health and Care Excellence (NICE) Reslizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 479
2017 National Institute for Health and Care Excellence (NICE) Tofacitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 480
2017 National Institute for Health and Care Excellence (NICE) Immunosuppressive therapy for kidney transplant in adults. NICE technology appraisal guidance 481
2017 National Institute for Health and Care Excellence (NICE) Immunosuppressive therapy for kidney transplant in children and young people. NICE technology appraisal guidance 482
2017 National Institute for Health and Care Excellence (NICE) Sarilumab for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 485
2017 National Institute for Health and Care Excellence (NICE) Aflibercept for treating choroidal neovascularisation. NICE technology appraisal guidance 486
2017 National Institute for Health and Care Excellence (NICE) Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours. NICE technology appraisal guidance 488
2017 National Institute for Health and Care Excellence (NICE) Vismodegib for treating basal cell carcinoma. NICE technology appraisal guidance 489
2017 National Institute for Health and Care Excellence (NICE) Naltrexone–bupropion for managing overweight and obesity. NICE technology appraisal guidance 494
2017 National Institute for Health and Care Excellence (NICE) Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. NICE technology appraisal guidance 496
2017 National Institute for Health and Care Excellence (NICE) Endobronchial valve insertion to reduce lung volume in emphysema. NICE interventional procedures guidance 600
2017 National Institute for Health and Care Excellence (NICE) Transcutaneous microwave ablation for severe primary axillary hyperhidrosis. NICE interventional procedures guidance 601
2017 National Institute for Health and Care Excellence (NICE) Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure. NICE interventional procedures guidance 602
2017 National Institute for Health and Care Excellence (NICE) Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. NICE interventional procedures guidance 603
2017 National Institute for Health and Care Excellence (NICE) Transvaginal mesh repair of anterior or posterior vaginal wall prolapse. NICE interventional procedures guidance 599
2017 National Institute for Health and Care Excellence (NICE) Processed nerve allografts to repair peripheral nerve discontinuities. NICE interventional procedures guidance 597
2017 National Institute for Health and Care Excellence (NICE) Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea. NICE interventional procedures guidance 598
2017 National Institute for Health and Care Excellence (NICE) Total distal radioulnar joint replacement for symptomatic joint instability or arthritis. NICE interventional procedures guidance 595
2017 National Institute for Health and Care Excellence (NICE) Extracranial to intracranial bypass for intracranial atherosclerosis. NICE interventional procedures guidance 596
2017 National Institute for Health and Care Excellence (NICE) Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease. NICE interventional procedures guidance 593
2017 National Institute for Health and Care Excellence (NICE) Ab externo canaloplasty for primary open-angle glaucoma. NICE interventional procedures guidance 591
2017 National Institute for Health and Care Excellence (NICE) High-intensity focused ultrasound for symptomatic breast fibroadenoma. NICE interventional procedures guidance 592
2017 National Institute for Health and Care Excellence (NICE) Radiofrequency treatment for haemorrhoids. NICE interventional procedures guidance 589
2017 National Institute for Health and Care Excellence (NICE) Transcatheter aortic valve implantation for aortic stenosis. NICE interventional procedures guidance 586
2017 National Institute for Health and Care Excellence (NICE) Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse. NICE interventional procedures guidance 581
2017 National Institute for Health and Care Excellence (NICE) Infracoccygeal sacropexy using mesh to repair uterine prolapse. NICE interventional procedures guidance 582
2017 National Institute for Health and Care Excellence (NICE) Sacrocolpopexy using mesh to repair vaginal vault prolapse. NICE interventional procedures guidance 583
2017 National Institute for Health and Care Excellence (NICE) Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse. NICE interventional procedures guidance 584
2017 National Institute for Health and Care Excellence (NICE) Endoscopic full thickness removal of non-lifting colonic polyps. NICE interventional procedures guidance 580
2017 National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating pancreatic cancer. NICE interventional procedures guidance 579
2017 National Institute for Health and Care Excellence (NICE) Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain. NICE interventional procedures guidance 578
2017 National Institute for Health and Care Excellence (NICE) Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women. NICE interventional procedures guidance 576
2017 National Institute for Health and Care Excellence (NICE) Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse. NICE interventional procedures guidance 577
2017 National Institute for Health and Care Excellence (NICE) Lateral interbody fusion in the lumbar spine for low back pain. NICE interventional procedures guidance 574
2017 National Institute for Health and Care Excellence (NICE) Trabecular stent bypass microsurgery for open-angle glaucoma. NICE interventional procedures guidance 575
2017 National Institute for Health and Care Excellence (NICE) SecurAcath for securing percutaneous catheters. NICE medical technologies guidance 34
2017 National Institute for Health and Care Excellence (NICE) ENDURALIFE powered CRT-D devices for treating heart failure. NICE medical technologies guidance 33
2017 National Institute for Health and Care Excellence (NICE) HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography. NICE medical technologies guidance 32
2017 National Institute for Health and Care Excellence (NICE) HumiGard for preventing inadvertent perioperative hypothermia. NICE medical technologies guidance 31
2017 National Institute for Health and Care Excellence (NICE) Tests in secondary care to identify people at high risk of ovarian cancer. NICE diagnostics guidance 31
2017 National Institute for Health and Care Excellence (NICE) Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis. NICE diagnostics guidance 29
2017 National Institute for Health and Care Excellence (NICE) Virtual chromoendoscopy to assess colorectal polyps during colonoscopy. NICE diagnostics guidance 28
2017 National Institute for Health and Care Excellence (NICE) Molecular testing strategies for Lynch syndrome in people with colorectal cancer. NICE diagnostics guidance 27
2017 Canary Health Service [Tools for early detection of disease-related malnutrition for adult population in the hospital setting]
2017 Canary Health Service [Safety, clinical effectiveness and cost-effectiveness of platelet-rich plasma for the treatment of chronic wounds]
2017 Canary Health Service [Cost-effectiveness of pneumococcal vaccination in adults older than 60 years]
2017 Canary Health Service [Argus II. Retinal Prosthesis System]
2017 Canary Health Service [High definition direct current transcranial stimulation (HD-tDCS) in Fibromyalgia]
2017 Canary Health Service [Effectiveness, safety and cost-effectiveness of the flash interstitial fluid glucose monitoring system (FreeStyle Libre®) for diabetes mellitus type 1 and 2 (Update Appendix)]
2017 Canary Health Service [Development of shared decision support tools derived from clinical practice guideline recommendations]
2017 Health Information and Quality Authority (HIQA) Systematic review of clinical guidelines on risk stratification during pregnancy
2017 Health Information and Quality Authority (HIQA) Clinical and cost-effectiveness of oral nutrition support interventions in hospitalised adults – evidence tables
2017 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Keep Walking endomedullary implant for external distal support prosthesis in patients with transfemoral amputation]
2016 Haute Autorite de sante (HAS) [Endovascular thrombectomy of intracranial arteries]
2016 NIHR Health Technology Assessment programme TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
2016 NIHR Health Technology Assessment programme A multicentre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and health-care resource use following cardiac surgery (TITRe2)
2016 NIHR Health Technology Assessment programme An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial)
2016 NIHR Health Technology Assessment programme Comparison Of iNfliximab and ciclosporin in Steroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT)
2016 NIHR Health Technology Assessment programme PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation
2016 NIHR Health Technology Assessment programme A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review
2016 NIHR Health Technology Assessment programme Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial
2016 NIHR Health Technology Assessment programme The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness
2016 NIHR Health Technology Assessment programme CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children
2016 NIHR Health Technology Assessment programme A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial